ARTES attends BioEurope Spring

METAVAX®-Platform

ARTES attends BioEurope 2019

ARTES and Burnet Institute publish data on production and immunogenicity of malaria transmission-blocking vaccine candidates

ARTES Biotech­nol­o­gy and Bur­net Insti­tute recent­ly pub­lished data on the effi­cient pro­duc­tion of malar­ia vac­cine can­di­dates using virus-like par­ti­cles (VLP) pre­sent­ing malar­ia trans­mis­sion-stage anti­gens, which were capa­ble of induc­ing trans­mis­sion-block­ing anti­bod­ies.

ARTES attends BioEurope Spring 2019

Meet us at the Bio-Europe Spring 2018 tak­ing place in Vien­na, Aus­tria March 25 ‑27. Volk­er Jen­zelews­ki, Direc­tor Tech­nol­o­gy at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­ma­ceu­ti­cal and vac­cine prod­ucts.

SplitCore – the latest milestone in ARTES´ vaccine development offer

ARTES Biotech­nol­o­gy announces the acqui­si­tion of the unique Split­Core tech­nol­o­gy devel­oped by sci­en­tists at the Uni­ver­si­ty of Freiburg, Ger­many.

ARTES and Minapharm joint forces

ARTES Biotech­nol­o­gy GmbH, Ger­many, and Minapharm Phar­ma­ceu­ti­cals and Chem­i­cal Indus­tries S.A.E., Egypt, joint­ly announced today the for­ma­tion of a new strate­gic busi­ness pact, offer­ing pack­et solu­tion for bio­phar­ma­ceu­ti­cal process­es .

 

Aim of this new strate­gic busi­ness coop­er­a­tion is to joint­ly out-license com­bi­na­tions of ARTES’ and Minapharm’s respec­tive pro­pri­etary tech­nolo­gies and prod­ucts to third par­ties world­wide. Both part­ners own and con­trol tech­nolo­gies for micro­bial and mam­malian recom­bi­nant cell lines, process­es and prod­ucts.

The already exist­ing and estab­lished part­ner­ship among the com­pa­nies bases on a suc­cess­ful, long last­ing busi­ness rela­tion­ship. In this, ARTES acts as spe­cial­ist for micro­bial cell line and process devel­op­ment for recom­bi­nant pro­teins and Minapharm on the oth­er hand is the major play­er for pro­duc­tion and mar­ket­ing of bio-phar­ma­ceu­ti­cals in the MENA region.

With the com­bi­na­tion of ARTES’ and Minapharm’s busi­ness intel­li­gence and ser­vice solu­tions future clients will ben­e­fit from our lat­est, inno­v­a­tive devel­op­ments ”, Dr. Michael Pio­ntek, Man­ag­ing direc­tor of ARTES stat­ed, “and will get robust, proven man­u­fac­tur­ing expe­ri­ence and prod­uct reg­is­tra­tion.” Proven safe­ty and effi­ca­cy of prod­ucts will team up with high yield and low cost man­u­fac­tur­ing tech­nol­o­gy.

The estab­lished alliance with ARTES con­tin­u­ous­ly con­firms Minapharm’s posi­tion as a region­al biotech leader. Our emer­gence as such con­tributes to a rad­i­cal shift in both inno­va­tion and afford­abil­i­ty of bio­phar­ma­ceu­ti­cals as a func­tion of time. We have been able to demon­strate the via­bil­i­ty of our strat­e­gy to offer patients in the devel­op­ing world with a time­ly ben­e­fit of nov­el ther­a­peu­tic pro­teins. Our bio­phar­ma­ceu­ti­cal pipeline port­fo­lio reflects great poten­tial to expand our strat­e­gy and offers solu­tions for the man­age­ment of med­ical emer­gen­cies. We are glad that ARTES is shar­ing our vision” said Frank Mueller, Senior Man­ag­er Bio­phar­ma­ceu­ti­cal Projects of Minapharm.

http://www.minapharm.com